Paricalcitol attenuates cyclosporine-induced kidney injury in rats

Kidney International

Volumn 77, Issue 12, 2012, Pages 1076-1085

  Park, Jeong Woo ^a   Bae, Eun Hui ^a   Kim, In Jin ^a   Ma, Seong Kwon ^a   Choi, Chan ^a   Lee, Jongun ^a   Kim, Soo Wan ^a  

^a Chonnam National University Medical School   (South Korea)

Author keywords

cyclosporine; fibrosis; inflammation; paricalcitol

Indexed keywords

COLLAGEN; CREATININE; CYCLOSPORIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PARICALCITOL; SMAD PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; CYCLOSPORIN; ERGOCALCIFEROL; PROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; CYCLOSPORIN INDUCED KIDNEY INJURY; DRUG INDUCED DISEASE; IN VITRO STUDY; KIDNEY FUNCTION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MALE; MONOCYTE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; FIBROSIS; INFLAMMATION; KIDNEY DISEASE; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; CYCLOSPORINE; ERGOCALCIFEROLS; FIBROSIS; INFLAMMATION; KIDNEY DISEASES; PROTECTIVE AGENTS; RATS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 77956893433     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.69     Document Type: Article

References (34)

1. Kuhlmann A, Haas CS, Gross ML et al. 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally nephrectomized rat. Am J Physiol Renal Physiol 2004; 286: F526-F533. (Pubitemid 38233647)
2. Makibayashi K, Tatematsu M, Hirata M et al. A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 2001; 158: 1733-1741. (Pubitemid 32422938)
3. Olesen ET, de Seigneux S, Wang G et al. Rapid and segmental specific dysregulation of AQP2, S256-pAQP2 and renal sodium transporters in rats with LPS-induced endotoxaemia. Nephrol Dial Transplant 2009; 24: 2338-2349.
4. Brown AJ, Dusso A, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol 1999; 277: 157-175.
5. Tan X, Li Y, Liu Y. Therapeutic role and potential mechanisms of active Vitamin D in renal interstitial fibrosis. J Steroid Biochem Mol Biol 2007; 103: 491-496. (Pubitemid 46401277)
6. Li Y, Spataro BC, Yang J et al. 1,25-Dihydroxyvitamin D inhibits renal interstitial myofibroblast activation by inducing hepatocyte growth factor expression. Kidney Int 2005; 68: 1500-1510. (Pubitemid 43173380)
7. Drüeke TB. Which vitamin D derivative to prescribe for renal patients. Curr Opin Nephrol Hypertens 2005; 14: 343-349. (Pubitemid 40863071)
8. Tan X, Li Y, Liu Y. Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006; 17: 3382-3393. (Pubitemid 44865281)
9. Tan X, Wen X, Liu Y. Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 2008; 19: 1741-1752.
10. Mizobuchi M, Morrissey J, Finch JL et al. Combination therapy with an angiotensin converting enzyme inhibitor and a vitamin D analog suppresses the progression of renal insufficiency in uremic rats. J Am Soc Nephrol 2007; 18: 1796-1806. (Pubitemid 46870316)
11. Myers BD, Ross J, Newton L et al. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699-705. (Pubitemid 14074555)
12. Chapman JR, Nankivell BJ. Nephrotoxicity of cyclosporin A: short-term gain, long-term pain? Nephrol Dial Transplant 2006; 21: 2060-2063. (Pubitemid 44295026)
13. Wang C, Salahudeen AK. Lipid peroxidation accompanies cyclosporine nephrotoxicity: effects of vitamin E. Kidney Int 1995; 47: 927-934.
14. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481-508.
15. Johnson DW, Saunders HJ, Johnson FJ et al. Cyclosporin exerts a direct fibrogenic effect on human tubulointerstitial cells: roles of insulin-like growth factor I, transforming growth factor beta1, and platelet-derived growth factor. J Pharmacol Exp Ther 1999; 289: 535-542. (Pubitemid 29156072)
16. Vieira Jr JM, Noronha IL, Malheiros DM et al. Cyclosporine-induced interstitial fibrosis and arteriolar TGF-beta expression with preserved renal blood flow. Transplantation 1999; 68: 1746-1753. (Pubitemid 30004807)
17. Miyajima A, Chen J, Lawrence C et al. Antibody to transforming growth factor-beta ameliorates tubular apoptosis in unilateral ureteral obstruction. Kidney Int 2000; 58: 2301-2313.
18. Li C, Yang CW, Park JH et al. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 2004; 286: F46-F57. (Pubitemid 38045041)
19. Lee SH, Li C, Lim SW et al. Attenuation of interstitial inflammation and fibrosis by recombinant human erythropoietin in chronic cyclosporine nephropathy. Am J Nephrol 2005; 25: 64-76. (Pubitemid 40529278)
20. Buffoli B, Pechánová O, Kojsová S et al. Provinol prevents CsA-induced nephrotoxicity by reducing reactive oxygen species, iNOS, and NF-kB expression. J Histochem Cytochem 2005; 53: 1459-1468. (Pubitemid 41720685)
21. Magendiramani V, Umesalma S, Kalayarasan S et al. S-allylcysteine attenuates renal injury by altering the expressions of iNOS and matrix metallo proteinase-2 during cyclosporine-induced nephrotoxicity in Wistar rats. J Appl Toxicol 2009; 29: 522-530.
22. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12. (Pubitemid 38020692)
23. Böttinger EP, Bitzer M. TGF-beta signaling in renal disease. J Am Soc Nephrol 2002; 13: 2600-2610.
24. Akool el-S, Doller A, Babelova A et al. Molecular mechanisms of TGF beta receptor-triggered signaling cascades rapidly induced by the calcineurin inhibitors cyclosporin A and FK506. J Immunol 2008; 181: 2831-2845.
25. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657. (Pubitemid 34579158)
26. Masaki T, Foti R, Hill PA et al. Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. Kidney Int 2003; 63: 1256-1264. (Pubitemid 36349991)
27. Chan ED, Riches DW. IFN-gamma + LPS induction of iNOS is modulated by ERK, JNK/SAPK, and p38(mapk) in a mouse macrophage cell line. Am J Physiol Cell Physiol 2001; 280: C441-C450.
28. Ma FY, Flanc RS, Tesch GH et al. A pathogenic role for c-Jun aminoterminal kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc Nephrol 2007; 18: 472-484. (Pubitemid 46193313)
29. Yang CW, Faulkner GR, Wahba IM et al. Expression of apoptosis-related genes in chronic cyclosporine nephrotoxicity in mice. Am J Transplant 2002; 2: 391-399. (Pubitemid 36306878)
30. Sanz AB, Santamaŕa B, Ruiz-Ortega M et al. Mechanisms of renal apoptosis in health and disease. J Am Soc Nephrol 2008; 19: 1634-1642.
31. Gadola L, Noboa O, Marquez MN et al. Calcium citrate ameliorates the progression of chronic renal injury. Kidney Int 2004; 65: 1224-1230. (Pubitemid 38406960)
32. Oldroyd SD, Miyamoto Y, Moir A et al. An IGF-I antagonist does not inhibit renal fibrosis in the rat following subtotal nephrectomy. Am J Physiol Renal Physiol 2006; 290: F695-F702. (Pubitemid 43724972)
33. Kim SW, Wang W, Nielsen J et al. Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. Am J Physiol Renal Physiol 2004; 286: F922-F935. (Pubitemid 38508993)
34. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408. (Pubitemid 34164012)